Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium
Standard
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium. / Melmer, Andreas; Fineder, Linda; Lamina, Claudia; Kollerits, Barbara; Dieplinger, Benjamin; Braicu, Ioana; Sehouli, Jalid; Cadron, Isabelle; Vergote, Ignace; Mahner, Sven; Zeimet, Alain G; Castillo-Tong, Dan Cacsire; Ebenbichler, Christoph F; Zeillinger, Robert; Dieplinger, Hans.
in: GYNECOL ONCOL, Jahrgang 128, Nr. 1, 01.01.2013, S. 38-43.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium
AU - Melmer, Andreas
AU - Fineder, Linda
AU - Lamina, Claudia
AU - Kollerits, Barbara
AU - Dieplinger, Benjamin
AU - Braicu, Ioana
AU - Sehouli, Jalid
AU - Cadron, Isabelle
AU - Vergote, Ignace
AU - Mahner, Sven
AU - Zeimet, Alain G
AU - Castillo-Tong, Dan Cacsire
AU - Ebenbichler, Christoph F
AU - Zeillinger, Robert
AU - Dieplinger, Hans
N1 - Copyright © 2012 Elsevier Inc. All rights reserved.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - OBJECTIVE: Comparative proteomics identified the plasma protein afamin as potential biomarker for ovarian cancer (OC). Significantly decreased afamin plasma concentrations in pre-therapeutic OC patients reconstituted to control values after successful tumor surgery. This study evaluates the association of afamin with survival and response to therapy in serous OC patients within the OVCAD consortium project.METHODS: We measured afamin in 215 pre-therapeutic plasma samples, 246 tumor lysates and 109 plasma samples taken 6months after finishing platinum-based chemotherapy. Differences in afamin plasma concentrations among FIGO stages were tested by Kruskal-Wallis test; association of afamin concentrations with overall and progression-free survival was evaluated using Kaplan-Meier survival plots and multivariate adjusted COX regression analysis.RESULTS: Pre-therapeutic afamin correlated significantly with FIGO stages (p=0.012) and was lower in the presence of metastases (p=0.013) and poorly differentiated OC in patients responding to therapy (p=0.016). Afamin ≥48.0mg/L was also associated with a lower hazard ratio for recurrent disease as compared to afamin <48.0mg/L (p=0.007). Post-therapeutic afamin ≥48mg/L was positively correlated with overall (p<0.001) and progression-free (p=0.012) survival and was lower in non-responders than in responders (p=0.048). Thus, afamin returned post-therapeutically to values of healthy controls in responders (p<0.001) but not in non-responders (p=0.114). Afamin in tumor lysates was lower in poorly differentiated OC than in G 1+2 tumors (p=0.041). Higher afamin concentrations in tumor lysates were associated with increased overall survival (p=0.003).CONCLUSION: These data indicate that afamin is associated with therapy response and survival rate in advanced OC patients.
AB - OBJECTIVE: Comparative proteomics identified the plasma protein afamin as potential biomarker for ovarian cancer (OC). Significantly decreased afamin plasma concentrations in pre-therapeutic OC patients reconstituted to control values after successful tumor surgery. This study evaluates the association of afamin with survival and response to therapy in serous OC patients within the OVCAD consortium project.METHODS: We measured afamin in 215 pre-therapeutic plasma samples, 246 tumor lysates and 109 plasma samples taken 6months after finishing platinum-based chemotherapy. Differences in afamin plasma concentrations among FIGO stages were tested by Kruskal-Wallis test; association of afamin concentrations with overall and progression-free survival was evaluated using Kaplan-Meier survival plots and multivariate adjusted COX regression analysis.RESULTS: Pre-therapeutic afamin correlated significantly with FIGO stages (p=0.012) and was lower in the presence of metastases (p=0.013) and poorly differentiated OC in patients responding to therapy (p=0.016). Afamin ≥48.0mg/L was also associated with a lower hazard ratio for recurrent disease as compared to afamin <48.0mg/L (p=0.007). Post-therapeutic afamin ≥48mg/L was positively correlated with overall (p<0.001) and progression-free (p=0.012) survival and was lower in non-responders than in responders (p=0.048). Thus, afamin returned post-therapeutically to values of healthy controls in responders (p<0.001) but not in non-responders (p=0.114). Afamin in tumor lysates was lower in poorly differentiated OC than in G 1+2 tumors (p=0.041). Higher afamin concentrations in tumor lysates were associated with increased overall survival (p=0.003).CONCLUSION: These data indicate that afamin is associated with therapy response and survival rate in advanced OC patients.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antineoplastic Combined Chemotherapy Protocols
KW - CA-125 Antigen
KW - Carrier Proteins
KW - Cystadenocarcinoma, Serous
KW - Female
KW - Glycoproteins
KW - Humans
KW - Middle Aged
KW - Neoplasm Staging
KW - Organoplatinum Compounds
KW - Ovarian Neoplasms
KW - Proportional Hazards Models
KW - Serum Albumin
U2 - 10.1016/j.ygyno.2012.09.032
DO - 10.1016/j.ygyno.2012.09.032
M3 - SCORING: Journal article
C2 - 23063758
VL - 128
SP - 38
EP - 43
JO - GYNECOL ONCOL
JF - GYNECOL ONCOL
SN - 0090-8258
IS - 1
ER -
